CYP11B1 Inhibitors
1 drugsAbout CYP11B1
CYP11B1 (cytochrome P450 11B1) is an enzyme crucial in steroid hormone biosynthesis, catalyzing the final steps of cortisol and aldosterone production in the adrenal glands.
CYP11B1 is a therapeutic target due to its role in hormone regulation; dysregulation of cortisol and aldosterone contributes to various conditions. Currently, there is no genetic evidence available linking CYP11B1 to specific diseases.
ISTURISA is the only FDA-approved drug targeting CYP11B1, developed by RECORDATI RARE for two indications. It is a small molecule, representing 100% of the modality landscape for this target.
Top CYP11B1 Drugs
RECORDATI RARE is the only company with an approved drug targeting CYP11B1.
The lack of competition suggests a high barrier to entry or an untapped market opportunity for other companies.
CYP11B1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CYP11B1, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could diversify the therapeutic options for CYP11B1.
CYP11B1 Clinical Trials 10 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on CYP11B1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 3 | 2 | 0 | 1 | 100% |
| Phase 3 | 2 | 2 | 0 | 0 | 100% |
| Phase 4 | 3 | 0 | 0 | 3 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
CYP11B1 Drug Approval Timeline (2020 - 2020)
ISTURISA was the first and most recent drug approved in 2020, representing a span of one year.
The recent approval of ISTURISA suggests a renewed interest in CYP11B1 as a target, but further development is needed.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 5 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on CYP11B1. A trial counts if an approved drug acting on CYP11B1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.